JPMorgan keeps EUR 295 target for Sartorius stock

Published on 10/13/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 22, 2026. Sartorius stock costs EUR 250.90 on October 13, 2026, down 0.83 percent versus the Xetra close EUR 253.00.

On October 12, 2026, JPMorgan kept its Overweight rating and EUR 295.00 target for Sartorius stock.
Sartorius has scheduled its nine-month 2026 results conference call for October 22, 2026.
Sartorius stock costs EUR 250.90 at Lang & Schwarz on October 13, 2026 at 1:36 p.m. CEST, down 0.83 percent versus the Xetra close of October 9, 2026.
The stock trades at a price to earnings ratio of 88.87 and has a market capitalization of EUR 17.4 billion.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

JPMorgan kept its Overweight rating and EUR 295.00 target for Sartorius stock in an analyst note dated October 12, 2026. The target lies 17.58 percent above the Lang & Schwarz price of EUR 250.90, giving the market a clear valuation reference without changing the bank's rating. The stock was trading at EUR 250.90 at Lang & Schwarz on October 13, 2026 at 1:36 p.m. CEST, down 0.83 percent versus the Xetra close of October 9, 2026 at EUR 253.00.

Results arrive on October 22

Sartorius has scheduled its nine-month 2026 results conference call for October 22, 2026, at 1:00 p.m. CEST, according to the company's investor-relations page. That date is the next defined calendar point for the stock after the latest analyst update.

Stock remains below its yearly high

Sartorius stock is EUR 21.00 below its 52-week high of EUR 271.90 and EUR 52.40 above its 52-week low of EUR 198.50, both as of October 13, 2026. The current price is therefore 7.72 percent below the yearly high, while the intraday quote remains inside the established range.

The price to earnings ratio is 88.87, and the market capitalization is EUR 17.4 billion as of October 13, 2026. Those figures place valuation at the center of the market debate, while JPMorgan's EUR 295.00 target offers a quantified comparison with the current euro price.

Comparison with peers

Sartorius: minus 0.83 percent, P/E 88.87, market capitalization EUR 17.4 billion.

Sartorius Stedim Biotech (Euronext Paris, EUR): plus 0.28 percent, P/E 70.66, market capitalization EUR 20.8 billion.

Merck KGaA (Xetra, EUR): plus 1.05 percent, P/E 25.68, market capitalization EUR 60.9 billion.

Price and valuation in view

For investors, the combination of a EUR 295.00 analyst target, a 7.72 percent gap to the 52-week high and a price to earnings ratio of 88.87 defines the current market picture. The scheduled October 22 results call supplies the next dated test for that valuation framework.

The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.